Chromatin-modifying proteins in cancer

被引：22
作者：
Fog, Cathrine K. [1 ]
Jensen, Klaus T. [1 ]
Lund, Anders H. [1 ]
机构：
[1] Univ Copenhagen, Ctr Epigenet, Biotech Res & Innovat Ctr, DK-1168 Copenhagen, Denmark
来源：
APMIS | 2007年 / 115卷 / 10期
关键词：
chromatin; epigenetics; cancer; DNA methylation; histone code;
D O I：
10.1111/j.1600-0463.2007.apm_776.xml.x
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Chromatin-modifying proteins mold the genome into areas that are accessible for transcriptional activity and areas that are transcriptionally silent. This epigenetic gene regulation allows for different transcriptional programs to be conducted in different cell types at different timepoints-despite the fact that all cells in the organism contain the same genetic information. A large amount of data gathered over the last decades has demonstrated that deregulation of chromatin-modifying proteins is etiologically involved in the development and progression of cancer. Here we discuss how epigenetic alterations influence cancer development and review known cancer-associated alterations in chromatin-modifying proteins.
引用
收藏
页码：1060 / 1089
页数：30
相关论文
共 340 条
  • [101] Graff JR, 1998, CANCER RES, V58, P2063
  • [102] GRAFF JR, 1995, CANCER RES, V55, P5195
  • [103] Isolation and embryonic expression of the novel mouse gene Hic1, the homologue of HIC1, a candidate gene for the Miller-Dieker syndrome
    Grimm, C
    Spörle, R
    Schmid, TE
    Adler, ID
    Adamski, J
    Schughart, K
    Graw, J
    [J]. HUMAN MOLECULAR GENETICS, 1999, 8 (04) : 697 - 710
  • [104] A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome
    Guy, J
    Hendrich, B
    Holmes, M
    Martin, JE
    Bird, A
    [J]. NATURE GENETICS, 2001, 27 (03) : 322 - 326
  • [105] PRDI-BF1 recruits the histone H3 methyltransferase G9a in transcriptional silencing
    Gyory, I
    Wu, J
    Fejér, G
    Seto, E
    Wright, KL
    [J]. NATURE IMMUNOLOGY, 2004, 5 (03) : 299 - 308
  • [106] Identification of a functionally impaired positive regulatory domain I binding factor 1 transcription repressor in myeloma cell lines
    Györy, I
    Fejér, G
    Ghosh, N
    Seto, E
    Wright, KL
    [J]. JOURNAL OF IMMUNOLOGY, 2003, 170 (06) : 3125 - 3133
  • [107] Upregulation and nuclear recruitment of HDACI in hormone refractory prostate cancer
    Halkidou, K
    Gaughan, L
    Cook, S
    Leung, HY
    Neal, DE
    Robson, CN
    [J]. PROSTATE, 2004, 59 (02) : 177 - 189
  • [108] SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells
    Hamamoto, R
    Furukawa, Y
    Morita, M
    Iimura, Y
    Silva, FP
    Li, MH
    Yagyu, R
    Nakamura, Y
    [J]. NATURE CELL BIOLOGY, 2004, 6 (08) : 731 - 740
  • [109] Enhanced SMYD3 expression is essential for the growth of breast cancer cells
    Hamamoto, R
    Silva, FP
    Tsuge, M
    Nishidate, T
    Katagiri, T
    Nakamura, Y
    Furukawa, Y
    [J]. CANCER SCIENCE, 2006, 97 (02) : 113 - 118
  • [110] HANADA M, 1993, BLOOD, V82, P1820
6789101112131415